Remdesivir and EIDD-1931 Interact with Human Equilibrative Nucleoside Transporters 1 and 2: Implications for Reaching SARS-CoV-2 Viral Sanctuary Sites
2021/09/09 by Siennah R. Miller, Meghan E. McGrath, Kimberley M. Zorn +3 · 21 citations
Biochemistry, Genetics and Molecular Biology · Medicine · #2019-20 coronavirus outbreak #Adenosine and Purinergic Signaling #Biology #Coronavirus disease 2019 (COVID-19) #Gene #Genetics #Infectious Encephalopathies and Encephalitis #Medicine #Neonatal Health and Biochemistry #Nucleoside #Nucleoside transporter #Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) #Transporter #Virology
paper · pdf · doi:10.1124/molpharm.121.000333
openalex publication_date 2021/09/09 · openalex created_date 2025/10/10 · openalex updated_date 2026/08/01
Cited by
- Molnupiravir: A new candidate for COVID-19 treatment. [europepmc]
- Response to Comments on "Remdesivir and EIDD-1931 Interact with Human Equilibrative Nucleoside Transporters 1 and 2: Implications for Reaching SARS-CoV-2 Viral Sanctuary Sites". [europepmc]
- Advances in Pathogenesis, Progression, Potential Targets and Targeted Therapeutic Strategies in SARS-CoV-2-Induced COVID-19. [europepmc]
- PF-07321332 (Nirmatrelvir) does not interact with human ENT1 or ENT2: Implications for COVID-19 patients. [europepmc]
- The potential of remdesivir to affect function, metabolism and proliferation of cardiac and kidney cells in vitro. [europepmc]
- A Newly Engineered A549 Cell Line Expressing ACE2 and TMPRSS2 Is Highly Permissive to SARS-CoV-2, Including the Delta and Omicron Variants. [europepmc]
- Inborn Errors of Nucleoside Transporter (NT)-Encoding Genes ( SLC28 and SLC29 ). [europepmc]
- Important roles of transporters in the pharmacokinetics of anti-viral nucleoside/nucleotide analogs. [europepmc]
- Preclinical Pharmacokinetics and In Vitro Properties of GS-441524, a Potential Oral Drug Candidate for COVID-19 Treatment. [europepmc]
- SARS-CoV-2 rebound with and without antivirals. [europepmc]
- Viral target and metabolism-based rationale for combined use of recently authorized small molecule COVID-19 medicines: Molnupiravir, nirmatrelvir, and remdesivir. [europepmc]
- Transporter Inhibition Profile for the Antivirals Tilorone, Quinacrine and Pyronaridine. [europepmc]
- Addressing the Clinical Importance of Equilibrative Nucleoside Transporters in Drug Discovery and Development. [europepmc]
- Interactions of the Anti-SARS-CoV-2 Agents Molnupiravir and Nirmatrelvir/Paxlovid with Human Drug Transporters. [europepmc]
- An active metabolite of the anti-COVID-19 drug molnupiravir impairs mouse preimplantation embryos at clinically relevant concentrations. [europepmc]
- Transporter modulation of molnupiravir and its metabolite β-D-N4-hydroxycytidine across the blood-brain barrier in a rat. [europepmc]
- Assessing the mitochondrial safety profile of the molnupiravir active metabolite, β-d-N4-hydroxycytidine (NHC), in the physiologically relevant HepaRG model. [europepmc]
- Comprehensive genotoxicity and carcinogenicity assessment of molnupiravir. [europepmc]
- Carboxylesterase Factors Influencing the Therapeutic Activity of Common Antiviral Medications Used for SARS-CoV-2 Infection. [europepmc]
- Severe acute respiratory syndrome coronavirus 2-mediated dysregulation of drug processing genes is dependent on pathogenic variants, target site of infection, age, and sex. [europepmc]
- Real-world effectiveness of molnupiravir and nirmatrelvir/ritonavir against mortality, hospitalization, and in-hospital outcomes among community-dwelling, ambulatory COVID-19 patients during the BA.2.2 wave in Hong Kong: an observational study [europepmc]